Investor Relations Home

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.05 (0.61%)
Data as of 08/21/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
08/02/18IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance
MOUNTAIN VIEW, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018. Second Quarter Highlights Cyclo G6™ product revenue increased approximately 58% year-over-year Shipped 11,500 G6 probes Shipped 125 G6 laser systems Approval of Cyclo G6 laser system in South Korea Total revenue of $10.3 million “I’m pleased with the strong Cyclo G6 momentum we saw in the s... 
Printer Friendly Version
07/19/18IRIDEX to Report Second Quarter 2018 Financial Results on August 2, 2018
MOUNTAIN VIEW, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2, 2018.  The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for internatio... 
Printer Friendly Version
07/10/18IRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped
Important Commercial Milestone Demonstrates Growing Worldwide Awareness of MicroPulse Technology for Treatment of Glaucoma MOUNTAIN VIEW, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser System, which utilizes the Company’s proprietary MicroPulse® technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefec... 
Printer Friendly Version
06/19/18IRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in Korea
MOUNTAIN VIEW, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS).  Currently available in more than 50 countries, the CYCLO G6 treats patients diagnosed with a range of glaucoma disease states using the Company’s proprietary MicroPulse® technology and a family of single use probes. “International expansion in the Asia-Pacific region remains a ... 
Printer Friendly Version
Primary IR Contact
Lynn Lewis or Leigh Salvo
Phone: (415) 937-5404

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina